Pricing Log in Create free account

Beam Therapeutics Inc. (BEAM) vs Enliven Therapeutics, Inc. (ELVN)

Beam Therapeutics Inc. and Enliven Therapeutics, Inc. are both Biotechnology companies. Enliven Therapeutics, Inc. is the larger, with a market value of $2.9B against $2.6B — 1.1× the size. Enliven Therapeutics, Inc. has the higher net margin (0.00% vs −55.5%) and the higher return on invested capital (0.00% vs −1,599.3%). Across the 14 metrics below, Beam Therapeutics Inc. leads on 7 and Enliven Therapeutics, Inc. on 7.

Valuation

Metric BEAM ELVN Biotechnology median
P/E n/m n/m 8.50
P/S 15.69 n/m 9.71
P/B 2.29 2.76 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.95 n/m 9.21
Earnings yield (3.49%) (4.47%) (33.15%)
Free cash flow yield (15.22%) (2.71%) (25.50%)

Profitability

Metric BEAM ELVN Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (242.27%) 0.00% 0.00%
Net margin (55.45%) 0.00% 0.00%
Free cash flow margin (238.90%) 0.00% 0.00%
Return on equity (8.18%) (15.31%) (56.36%)
Return on assets (6.23%) (14.98%) (48.04%)
Return on invested capital (1,599.30%) 0.00% 0.00%

Growth

Metric BEAM ELVN Biotechnology median
Revenue growth (TTM) 158.88% — 6.02%
EPS growth (last fiscal year) 82.31% 3.17% 30.26%
Revenue growth, 5-year CAGR 466.27% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM ELVN Biotechnology median
Debt to equity 0.09 0.00 0.00
Current ratio 14.57 64.07 4.72
Net debt to EBITDA 3.30 3.87 0.96

Dividend

Metric BEAM ELVN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BEAM ELVN Biotechnology median
Market cap 2.55b 2.88b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack